Details

Autor(en) / Beteiligte

• Ginzler, Ellen M
• Wax, Stephen
• Rajeswaran, Anand
• Copt, Samuel
• Hillson, Jan
• Ramos, Eleanor
• Singer, Nora G

Titel

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial

Ist Teil von

• Arthritis research & therapy, 2012-02, Vol.14 (1), p.R33-R33

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2012

Link zum Volltext

Quelle

Springer Nature - Complete Springer Journals

Beschreibungen/Notizen

• Atacicept is a soluble, fully human, recombinant fusion protein that inhibits B cell-stimulating factors APRIL (a proliferation-inducing ligand) and BLyS (B-lymphocyte stimulator). The APRIL- LN study aimed to evaluate the efficacy and safety of atacicept in patients with active lupus nephritis (LN), receiving newly initiated corticosteroids (CS) and mycophenolate mofetil (MMF). This was a randomized, double-blind, placebo-controlled Phase II/III, 52-week study. At screening (Day -14), patients initiated high-dose CS (the lesser of 0.8 mg/kg/day or 60 mg/day prednisone) and MMF (1 g daily, increased by 1 g/day each week to 3 g daily). From Day 1, atacicept (150 mg, subcutaneously, twice weekly for 4 weeks, then weekly) was initiated with MMF along with a tapered dose of CS. The trial was terminated after the enrollment of six patients, due to an unexpected decline in serum immunoglobulin G (IgG) and the occurrence of serious infections. Efficacy was thus not evaluated. By Day 1, serum IgG levels had declined substantially in patients then randomized to atacicept (n = 4) compared with placebo (n = 2). Patients receiving atacicept also had more severe proteinuria on Day -14 than those on placebo. Lymphocyte counts were low at screening in all patients. IgG decline continued following initiation (Day 1) of atacicept. Three atacicept-treated patients developed serum IgG below the protocol-defined discontinuation threshold of 3 g/l, two of whom developed serious pneumonia. Future studies are needed to characterize the safety, efficacy, and pharmacodynamic response of atacicept in LN patients. ClinicalTrials.gov: NCT00573157.